logo
Almonty Appoints Respected U.S.-Based Financial Executive Brian Fox as Chief Financial Officer

Almonty Appoints Respected U.S.-Based Financial Executive Brian Fox as Chief Financial Officer

Business Wire6 days ago
TORONTO--(BUSINESS WIRE)--Almonty Industries Inc. (' Almonty ' or the ' Company ') (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten critical to the U.S. defense and technology sectors, today announced the appointment of Brian Fox, CPA as Chief Financial Officer, succeeding Mark Gelmon, CPA,CA, effective August 25, 2025.
Mr. Fox most recently served as Chief Financial & Operating Officer at CBIZ Marks Paneth, a top-tier U.S. accounting and advisory firm, where he played a key role in strategic growth initiatives and post-merger integration. His prior experience includes leadership roles at Loureiro Engineering and United Subcontractors, as well as senior audit work at Arthur Andersen. He holds a Master's degree in Management from Harvard University and a Bachelor of Science in Accounting from the University of Connecticut.
Mr. Gelmon, who joined Almonty in 2015 through its acquisition of Woulfe Mining Corp. (former owner of the Sangdong Mine Project) and became CFO in 2017, will remain involved with the Company as a financial consultant. The Company thanks Mr. Gelmon for his unwavering dedication and years of service.
Lewis Black, Chief Executive Officer of Almonty, commented: 'As Almonty advances its U.S. redomiciling strategy following our successful US$90 million public offering and Nasdaq listing, the appointment of a U.S.-based executive with deep financial and operational acumen was a deliberate and strategic move. Brian brings exactly the type of disciplined execution and institutional-grade financial leadership we need as we scale operations and align with U.S. capital markets. His track record in guiding complex organizations through growth and transformation will prove invaluable. We thank Mark for his years of dedication and are thrilled to welcome Brian to the team.'
About Almonty
Almonty (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1) is a leading supplier of conflict-free tungsten – a strategic metal critical to the defense and advanced technology sectors. As geopolitical tensions heighten, tungsten has become essential for armor, munitions, and electronics manufacturing. Almonty's flagship Sangdong Mine in South Korea, historically one of the world's largest and highest-grade tungsten deposits, is expected to supply over 80% of global non-China tungsten production upon reaching full capacity, directly addressing critical supply vulnerabilities highlighted by recent U.S. defense procurement bans and export restrictions by China. With established operations in Portugal and additional projects in Spain, Almonty is strategically aligned to meet rapidly rising demand from Western allies committed to supply-chain security and defense readiness. To learn more, please visit https://almonty.com.
Legal Notice
The release, publication, or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published, or distributed should inform themselves about and observe such restrictions.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Information
This news release contains 'forward-looking statements' and 'forward-looking information' within the meaning of applicable securities laws.
All statements, other than statements of present or historical facts, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are typically identified by words such as 'plan', 'development', 'growth', 'continued', 'intentions', 'expectations', 'emerging', 'evolving', 'strategy', 'opportunities', 'anticipated', 'trends', 'potential', 'outlook', 'ability', 'additional', 'on track', 'prospects', 'viability', 'estimated', 'reaches', 'enhancing', 'strengthen', 'target', 'believes', 'next steps' or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements concerning the completion of the Offering, the Company's redomiciling initiatives, the Company's position as a leading supplier of tungsten to the U.S. and its allies, the timing of any listing of the Common Shares on the Nasdaq, the continued listing of the Common Shares on the TSX and the ASX and trading on the Frankfurt Stock Exchange, and the use of proceeds of the Offering.
Forward-looking statements are based upon certain assumptions and other important factors that, if untrue, could cause actual results to be materially different from future results expressed or implied by such statements. There can be no assurance that forward-looking statements will prove to be accurate. Key assumptions upon which the Company's forward-looking information is based include, without limitation, the absence of market conditions that could adversely impact the Offering or the intended listing of the Common Shares on the Nasdaq; the satisfaction of all listing requirements of the Nasdaq and continued listing requirements of the TSX and ASX; the achievement of any closing conditions to the Offering; and the absence of material adverse changes in the Company's industry or the global economy including interest rates, inflationary pressures, supply chain disruptions, and commodity market volatility.
Forward-looking statements are also subject to risks and uncertainties facing the Company's business, including, without limitation, the risks and uncertainties identified in the Registration Statement; risks relating to the Offering not being completed in a timely manner or at all, including due to unfavourable market or other conditions or factors; the possibility that the required approvals for or conditions to the Offering will not be received or satisfied on a timely basis or at all; changes in the anticipated timing for closing the Offering; business disruption during the pendency of or following the Offering; diversion of management time on Offering-related issues; the ability to retain members of Almonty's management team; the impact of the Offering on relationships with customers, suppliers, employees and other business counterparties; risks related to the reaction of customers, shareholders and members of the public to the Offering; and other events that could adversely impact the completion of the Offering, including industry or economic conditions outside of Almonty's control. Any of these risks could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. Readers should consider reviewing the detailed risk discussion in the Company's Registration Statement, the most recent Annual Information Form and the amended Management Discussion and Analysis for the three months ended March 31, 2025 filed on SEDAR+, for a fuller understanding of the risks and uncertainties that affect the Company's business and operations.
Although Almonty has attempted to identify important factors that could cause actual results, level of activity, performance or achievements to differ materially from those contained in forward-looking statements, there may be other factors that cause results, level of activity, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and even if events or results described in the forward-looking statements are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, Almonty. Accordingly, readers should not place undue reliance on forward-looking statements and are cautioned that actual outcomes may vary.
Investors are cautioned against attributing undue certainty to forward-looking statements. Almonty cautions that the foregoing list of material factors is not exhaustive. When relying on Almonty's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Can Super Micro's AI Demand Outpace Profit Margin Fears?
Can Super Micro's AI Demand Outpace Profit Margin Fears?

Yahoo

time13 minutes ago

  • Yahoo

Can Super Micro's AI Demand Outpace Profit Margin Fears?

Super Micro Computer (NASDAQ:SMCI) is navigating a complex market landscape as it prepares to report its fiscal fourth-quarter earnings with a significant long-term growth narrative in the AI server space tempered by immediate concerns about market visibility and sustained pressure on profit margins. The company's heavy reliance on key suppliers and a competitive environment, where large-scale deals and component costs weigh on profitability, creates a cautious outlook despite its strong position as a leading beneficiary of rising AI infrastructure spending. Analyst Matt Bryson of Wedbush, in a note released on Monday, reiterated a Neutral rating on Super Micro with a $30 price forecast ahead of the company's earnings report scheduled for August the analyst acknowledged Super Micro's positioning as a key beneficiary of accelerating AI infrastructure spend, particularly in the server market, he expressed caution over near-term visibility and uncertainty around actual demand strength. Bryson noted that Super Micro stands to benefit from secular trends that align with its core strengths. Spending from neocloud providers, AI model builders, and sovereign buyers continues to grow, and these customers are increasingly turning to OEMs like Super Micro and Dell Technologies (NYSE:DELL) to meet their AI server requirements. He added that Nvidia's (NASDAQ:NVDA) apparent prioritization of GB200 deliveries to OEMs, rather than directly to hyperscalers, could serve as a tailwind for Super Micro. Peer company Gigabyte, for example, recently reported a 50% quarter-over-quarter sales surge, a result Bryson attributed to increased AI server shipments. If current market dynamics hold, Bryson sees a long-term path for Super Micro to potentially reach $10 billion in quarterly sales, echoing targets previously laid out by Super Micro CEO Charles Liang. This would be a significant leap from the $5.9 billion revenue consensus for fiscal fourth quarter and the $6.4 billion projection for calendar first quarter. However, Bryson underscored that visibility into Super Micro's actual build and demand trends remains limited. The company's heavy reliance on related parties for component sourcing and manufacturing complicates tracking real-time activity. Additionally, data from third-party sources has yet to reflect the level of demand surge expected from recent AI server trends. While strength in Taiwan-based suppliers like Wistron suggests a robust upstream environment, Bryson's team has not been able to confirm that Super Micro is directly seeing similar momentum in its own sales funnel. Margins also remain a key concern. Gross margins are expected to stay under pressure in the near term due to an increasing share of Nvidia (NASDAQ:NVDA) content in Super Micro's bill of materials. According to conversations with ODMs and OEMs, GB200-based designs leave little room for differentiation, further compressing vendor margins. Management has guided fiscal fourth-quarter gross margins to remain around 10%, roughly in line with the 9.7% margin reported in the previous quarter. The analyst characterized this conservatism as prudent, citing the lower-margin profile of large-scale deals, rising Nvidia component costs, and a lack of meaningful relief in memory pricing. For the fiscal fourth quarter, Super Micro management projected revenue in the range of $5.6 billion to $6.4 billion and adjusted earnings per share between 40 cents and 50 cents. Operating expenses are expected to reach $245 million, with an adjusted tax rate of 16.5%. The fully diluted share count is projected at 642 million, and capital expenditures are guided between $45 million and $55 million. Despite Super Micro's significant share price appreciation over the past few months, Bryson remains on the sidelines. Price Action: SMCI shares were trading higher by 3.88% to $58.84 at last check Monday. Image via Shutterstock Latest Ratings for SMCI Date Firm Action From To May 2021 Susquehanna Maintains Positive May 2021 Northland Capital Markets Maintains Outperform Jun 2020 Northland Capital Markets Initiates Coverage On Outperform View More Analyst Ratings for SMCI View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? SUPER MICRO COMPUTER (SMCI): Free Stock Analysis Report This article Can Super Micro's AI Demand Outpace Profit Margin Fears? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos
TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos

Yahoo

time13 minutes ago

  • Yahoo

TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos

Aug 4 - Tesla (NASDAQ:TSLA) is not shy about betting big on Elon Musk. The company just approved a fresh 96 million-share compensation package for its CEO, worth around $29 billion. It's all about keeping Musk locked in, especially after a Delaware court tossed out his original $50 billion pay deal from 2018, calling it unfair to shareholders. Now, Musk is fighting that ruling in court. But in the meantime, Tesla's board put together a new plan. The shares won't vest unless Musk stays in a top executive role through 2027, and even then, they come with a five-year holding period. Tesla also says there won't be any double-dipping if his old package gets reinstated. All this is happening while Tesla faces real challenges. Sales are down, the Cybertruck hasn't delivered, and competition from legacy automakers like General Motors (NYSE:GM), Hyundai (HYMTF), and BMW (BMWYY) is heating up. On top of that, Musk's political moves haven't helped Tesla's brand loyalty. Still, this new award could help steady the ship, at least if Musk sticks around. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

Yahoo

time13 minutes ago

  • Yahoo

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings. What Happened TG Therapeutics reported second-quarter earnings per share of 17 cents, up from 4 cents a year ago, but below the consensus of 19 cents. The multiple sclerosis-focused company reported sales of $141.15 million, up from $73.5 million a year ago, missing the consensus of $146.42 the second quarter of 2025, Briumvi's U.S. net product revenue surged to $138.8 million, marking a significant 91% increase year-over-year and a 16% rise from the previous quarter. The drug's commercialization is also expanding globally with the company's partner, Neuraxpharm, with Briumvi now approved in the European Union, the United Kingdom, Switzerland, and Australia. Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025. TG Therapeutics anticipates that cash, cash equivalents, and investment securities as of June 30, 2025, combined with the projected revenues from Briumvi, will be sufficient to fund the business based on the current operating plan. Pipeline Development Patient enrollment was commenced in the randomized Phase 3 pivotal program to evaluate a consolidated Day 1 and Day 15 dosing regimen for IV Briumvi in the ongoing ENHANCE trial. View more earnings on TGTX The company has dosed the first patient with progressive multiple sclerosis in the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases. Guidance 'The strong uptake we're seeing, combined with deepening physician confidence and compelling patient experiences, underscores the strength of our launch strategy and gives us confidence in reaching our updated 2025 full year BRIUMVI U.S. net revenue guidance of $570 to $575 million,' said Michael Weiss, Chairman and CEO. TG Therapeutics raised its 2025 revenue outlook for Briumvi to a range of $570 million to $575 million, up from its previous guidance of $560 million. However, this is still below the consensus estimate of $596.12 million. TG Therapeutics raised fiscal 2025 Briumvi's U.S. net product revenue target to $570 million-$575 million from $560 million in prior guidance versus consensus estimate of $596.12 million. The company raised total global revenue target to approximately $585 million for the full year 2025 (prior guidance of $575 million for full year 2025). Price Action: TGTX stock is trading lower by 14.6% to $29.91 at last check Monday. Read Next:Photo by Piotr Swat via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store